Scholar Rock in Phase 3 for Spinal Muscular Atrophy Treatment

 

• Topline data from Phase 3 trial expected in Q4 2024
• Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023 World Muscle Society (WMS) Annual Congress
• Apitegromab is the only muscle-targeted therapy candidate with clinical data showing proof of concept in spinal muscular atrophy

https://www.biospace.com/article/releases/scholar-rock-announces-completion-of-enrollment-for-the-phase-3-sapphire-trial/